Activist investor Ananym Capital Management has built a stake in Bio-Techne Corp. and is pushing the board to conduct a strategic review that would include a potential sale.

In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, ...

Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal. Bio-Techne's board has ...

Merck’s $11.3B Bio‑Techne deal spotlights life sciences tools stocks. Check top 10 quant-rated healthcare stocks ...

Merck KGaA, Darmstadt, Germany and Bio-Techne Corp., a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, ...

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the ...

Merck will buy Minneapolis-based Bio-Techne Corp. in a deal worth $11.3 billion. Bio-Techne was under pressure from an ...

Merck KGaA, Darmstadt, Germany, has agreed to acquire Bio-Techne for approximately $11.3 billion, the companies said today, in a deal designed to position the buyer as more of a leader across the life ...

Bio-Techne Corp. (NASDAQ:TECH) is one of the 9 Stocks Winning by Double Digits. Bio-Techne rallied for a third straight day on Thursday, surging 20.08 percent to close at $70.70 apiece, as investors ...

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation, a Minneapolis-based ...

With a new name and a new CEO, Bio-Techne has begun an aggressive growth strategy to ensure that researchers know not only its flagship brand, R&D Systems, but the company as a whole. One year ago, ...